A Systematic Overview of Radiation Therapy Effects in Skeletal Metastases

References

• Landis SH, Murray T, Bolden W. Cancer statistics, 1998. CA Cancer J Clin 48: 6–29. (01)
   Google Scholar
• Barton MB, Dawson R, Jacob S, CUrrOW D, Stevens G, Morgan G. Palliative radiotherapy of bone metastases: an evaluation of outcome measures. J Eval Clin Pract 2001; 7:47-64. (L1)
   PubMedGoogle Scholar
• Ciezki J, Macklis RM. The palliative role of radiotherapy in the management of the cancer patient. Semin Oncol 1995; 22: 82-90. (L2)
   Google Scholar
• Frassica DA, Thurman S, Welsh J. Radiation therapy. Orthop Clin North Am 2000; 31: 557-66. (L2)
   Google Scholar
• Friedland J, Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am 1999; 26: 391-402. (L1)
   PubMedGoogle Scholar
• Hoskin PJ. Radiotherapy in the management of bone pain. Clin Orthop 1995; 312: 105-19. (L1)
   Google Scholar
• Janjan NA. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997; 80: 1628-45. (L1)
   PubMedGoogle Scholar
• McEvan AJB. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 1997; 2: 165-82. (L1)
   Google Scholar
• Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420-4. (L1)
   Google Scholar
• Gokaslan ZL. Spine surgery for cancer. Curr Opin Oncol 1996; 8: 178-81. (L2)
   Google Scholar
• Janjan NA. Radiotherapeutic management of spinal metas-tases. J Pain Symptom Manage 1996; 11: 47-56. (L1)
   PubMedGoogle Scholar
• McLain RF, Bell GR. Newer management options in patients with spinal metastasis. Cleve Clin J Med 1998; 65: 359-67. (L1)
   Google Scholar
• Wedin R, Bauer HC, Wersäll P. Failures after operation for skeletal metastatic lesions of long bones. Clin Orthoped Relat Res 1999; 358: 128-39. (L1)
   Google Scholar
• Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16: 1218-25. (L1)
   PubMedGoogle Scholar
• Coleman RE. How can we improve the treatment of bone metastases further? Curr Opin Oncol 1998; 10: 7-13. (L1)
   Google Scholar
• Hillner BE, Ingle JN, Berenson JR, et al. American society of clinical oncology guidelines on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18: 1378-91. (L1)
   Google Scholar
• Ben-Josef E, Shamsa F, Williams AO, Porter AT. Radio-therapeutic management of osseous metastases: a survey of current patterns of care. Int J Radiat Oncol Biol Phys 1998; 40: 915–21. (02)
   Google Scholar
• Kirkbride P, Mackillop WJ, Priestman TJ, Browman G, Gospodarowicz M, Rousseau P. The role of palliative radio-therapy for bone metastases. Can J Oncol 1996; 6: 33-8. (L2)
   PubMedGoogle Scholar
• Rose CM, Kagan AR. The final report of the expert panel for the radiation oncology bone metastasis working group of the American College of Radiology. Int J Radiat Oncol Biol Phys 1998; 40: 1117-24. (02)
   Google Scholar
• Gaze MN, Kelly CG, Kerr GR, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schedules. Radiother Oncol 1997; 45: 109-16. (C2/265)
   Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys 1998; 42: 161-7. (C2/327)
   Google Scholar
• Koswig S, Budach V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 x 3 Gy vs. 1 x 8 Gy). A prospective study. Strahlenther Onkol 1999; 175: 500–8. (C2/107)
   PubMed Web of Science ®Google Scholar
• Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998; 47: 233-40. (C1/239)
   Google Scholar
• Niewald M, Tkocz HJ, Abel U, et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int J Radiat Oncol Biol Phys 1996; 36: 1085-9. (C2/97)
   Google Scholar
• Rasmusson B, Vejborg I, Jensen AB, et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiat Oncol 1995; 34: 179-84. (C2/200)
   Google Scholar
• Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52: 101-9. (C1/1157)
   Google Scholar
• The Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999; 52: 111-21. (C1/761)
   Google Scholar
• Arcangeli G, Giovinazzo G, Saracino B, et al. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 1998; 42: n19-26. (P2/255)
   Google Scholar
• Bremer M, Rades D, Blach M, et al. Effectiveness of hypofractionated radiotherapy in painful bone metastases. Two prospective studies with 1 x 4 Gy and 4 x 4 Gy. Strah-lenther Onkol 1999; 175: 382–6. (P1/146)
   PubMedGoogle Scholar
• Huguenin PU, Kieser S, Glanzmann C, et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. Int J Radiat Oncol Biol Phys 1998; 41: 401-5. (P3/40)
   Google Scholar
• Tombolini V, Zurlo A, Montagna A, et al. Radiation therapy of spinal metastases: results with different fractionations. Tumouri 1994; 80: 353-6. (P2/103)
   Google Scholar
• Uppelschoten JM, Wanders SL, de Jong JM. Single-dose radiotherapy (6 Gy): palliation in painful bone metastases. Radiother Oncol 1995; 36: 198–202. (P2/211)
   Google Scholar
• McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Uppdate Software (Systematic Review).
   Google Scholar
• Salazar OR, Sandhu T, Motta NW, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the international atomic energy agency (IAEA). Int J Radiat Oncol Biol Phys 2001; 50: 765-75. (C1/156)
   Google Scholar
• Chua ET, Chua EJ, Sethi VK. Half body irradiation for palliation of widespread metastatic bone disease. Ann Acad Med Singapore 1994; 23: 204-8. (R3/134)
   Google Scholar
• Ben-Josef E, Shamsa F, Youssef E, Porter AT. External beam radiotherapy for painful osseous metastases: pooled data dose response analysis. Int J Radiat Oncol Biol Phys 1999; 45: 715–9. (02)
   Google Scholar
• Ratanatharathom V, Powers WE, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999; 44: 1-18. (L1)
   PubMedGoogle Scholar
• Kal HB. Single-dose radiotherapy for painful bone metastases. Strahlenther Onkol 1999; 175: 495-9. (L2)
   Google Scholar
• Kida A, Taniguchi S, Fukuda H, Sakai K. Radiation therapy for metastatic spinal tumours. Radiat Med 2000; 18: 15-20. (R2/52)
   Google Scholar
• Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand 1996; 94: 269–75. (P1/153)
   PubMed Web of Science ®Google Scholar
• Katagiri H, Takahashi M, Inagaki J, et al. Clinical results of nonsurgical treatment for spinal metastases. Int J Radiat Oncol Biol Phys 1998; 42: 1127-32. (P2/82)
   Google Scholar
• Maranzano E, Latini P, Perrucci E, et al. Short-course radio-therapy (8 Gy x 2) in metastatic spinal cord compression: an effective and feasible treatment. Int J Radiat Oncol Biol Phys 1997; 38: 1037-44. (P2/49)
   Google Scholar
• Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995; 32: 959-67. (P2/209)
   Google Scholar
• Haentjens P, De Neve W, Opdecam P. Prosthesis for the treatment of metastatic bone disease of the hip: effects of radiotherapy. Bull Cancer 1995; 82: 961-70. (R2/28)
   Google Scholar
• Townsend PW, Rosenthal HG, Smalley SR, et al. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J Clin Oncol 1994; 12: 2345-50. (R2/64)
   Google Scholar
• Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radio-therapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40. (C1/305)
   Google Scholar
• Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of153Sm-ethylenediaminetetramethylenephosphonate(EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33: 1583-91. (C2/114)
   Google Scholar
• Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-81. (C1/118)
   Google Scholar
• Ahonen A, Joensuu H, Hiltunen J, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38: 123-7. (P2/35)
   Google Scholar
• Alberts AS, Smit BJ, Louw WKA, et al. Dose response relationship and multiple dose efficacy and toxicity of samar-ium-153-EDTMP in metastic cancer to bone. Radiother Oncol 1997; 43: 175-9. (P1/82)
   Google Scholar
• Baziotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998; 55: 377-81. (P2/64)
   Google Scholar
• Bos SD. An overview of current clinical experience with strontium-89 (Metastron). Prostate Suppl 1994; 5: 23-6. (P2/ 28)
   Google Scholar
• Kolesnikov-Gauthier H, Carpentier P, Depreux P, et al. Evaluation of toxicity and efficacy of 186 Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 2000; 41: 1689–94. (P3/ 28)
   Google Scholar
• Kraeber-Bodere F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000; 27: 1487–93. (P1/94)
   Google Scholar
• Lee CK, Aeppli DM, Unger J, et al. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol 1996; 19: 102-7. (P3/28)
   Google Scholar
• Liepe K, Hliscs R, Kropp J, et al. Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother Radio-pharm 2000; 15: 261-5. (P3/15)
   Google Scholar
• Piffanelli A, Dafermou A, Giganti M, et al. Radionuclide therapy for painful bone metastases. Q J Nucl Med 2001; 45: 100-7. (P2/610)
   Google Scholar
• Sciuto R, Tofani A, Giannarelli D, et al. Short- and long-term effects of 186 Re-1, 1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41: 647-54. (P1/65)
   Google Scholar
• Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999; 26: 2-7. (P2/105)
   Google Scholar
• Giammarile F, Mognetti T, Blondet C, et al. Bone pain palliation with 855r therapy. J Nucl Med 1999; 40: 585-90. (R1/119)
   Google Scholar
• Samarium-153-lexidronam for bone pain due to skeletal metastases. Canberra: Medicare Services Advisory Committee (MSAC). 0642415137. MSAC application 101. 1999.24. (Sys-tematic Review).
   Google Scholar
• Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91. (C1/380)
   Google Scholar
• Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17: 846-54. (C1/371)
   Google Scholar
• Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200. (C2/280)
   Google Scholar
• Berenson JR, Lichtenstein A. Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593-602. (C2/ 377)
   Google Scholar